Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center

[1]  M. Tunney,et al.  British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.

[2]  J. Chalmers,et al.  Bronchiectasis: new therapies and new perspectives. , 2018, The Lancet. Respiratory medicine.

[3]  W. Vach,et al.  Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency , 2017, The Journal of Allergy and Clinical Immunology: In Practice.

[4]  R. Hubbard,et al.  Bronchiectasis and the risk of cardiovascular disease: a population-based study , 2016, Thorax.

[5]  C. Marquette,et al.  Phenotyping Adults with Non-Cystic Fibrosis Bronchiectasis: A 10-Year Cohort Study in a French Regional University Hospital Center , 2016, Respiration.

[6]  D. White,et al.  Shared Decision-Making in Intensive Care Units. Executive Summary of the American College of Critical Care Medicine and American Thoracic Society Policy Statement. , 2016, American journal of respiratory and critical care medicine.

[7]  A. Torres,et al.  Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. , 2015, Annals of the American Thoracic Society.

[8]  M. McGuckin,et al.  Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. , 2015, Annals of the American Thoracic Society.

[9]  A. Fischer,et al.  Pulmonary manifestations in adult patients with chronic granulomatous disease , 2015, European Respiratory Journal.

[10]  A. Fischer,et al.  Prevention of infections during primary immunodeficiency. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Umadevi A. Muthukumaru,et al.  Efficacy of azithromycin in the treatment of bronchiectasis , 2014, Respirology.

[12]  É. Oksenhendler,et al.  Clinical picture and treatment of 2212 patients with common variable immunodeficiency. , 2014, The Journal of allergy and clinical immunology.

[13]  M. McGuckin,et al.  A novel microbiota stratification system predicts future exacerbations in bronchiectasis. , 2014, Annals of the American Thoracic Society.

[14]  T. Nawrot,et al.  Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. , 2014, Respiratory medicine.

[15]  B. Fevang,et al.  Lung disease, T-cells and inflammation in common variable immunodeficiency disorders , 2013, Scandinavian journal of clinical and laboratory investigation.

[16]  J. Lordan,et al.  Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. , 2013, Respiratory medicine.

[17]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[18]  Kathryn J. Quigley,et al.  Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis , 2013, Clinical and experimental immunology.

[19]  C. Olveira,et al.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score , 2012, European Respiratory Journal.

[20]  N. Thomson,et al.  Long‐term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  N. Karalus,et al.  Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[22]  M. Strek,et al.  Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. , 2012, Chest.

[23]  A. Fischer,et al.  Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. , 2012, The Journal of allergy and clinical immunology.

[24]  E. Paul,et al.  Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. , 2011, Journal of Allergy and Clinical Immunology.

[25]  J. Orange,et al.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. , 2010, Clinical immunology.

[26]  W. Boersma,et al.  Immunomodulatory Effects of Macrolide Antibiotics – Part 1: Biological Mechanisms , 2010, Respiration.

[27]  E. López-Granados,et al.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. , 2010, The Journal of allergy and clinical immunology.

[28]  A. Schäffer,et al.  Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. , 2010, The Journal of allergy and clinical immunology.

[29]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[30]  J. Litzman,et al.  Mannose‐binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency , 2008, Clinical and experimental immunology.

[31]  V. Bonagura,et al.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. , 2008, The Journal of allergy and clinical immunology.

[32]  É. Oksenhendler,et al.  Infections in 252 patients with common variable immunodeficiency. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[34]  M. Parsek,et al.  Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms , 2007, Antimicrobial Agents and Chemotherapy.

[35]  R. Wilson,et al.  Aetiology in adult patients with bronchiectasis. , 2007, Respiratory medicine.

[36]  P. King,et al.  Characterisation of the onset and presenting clinical features of adult bronchiectasis. , 2006, Respiratory medicine.

[37]  N. Rezaei,et al.  Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[38]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[39]  E. Pallisa,et al.  Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. , 2004, International immunopharmacology.

[40]  M. Keogan,et al.  An investigation into causative factors in patients with bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[41]  C. Cunningham-Rundles,et al.  Common variable immunodeficiency: clinical and immunological features of 248 patients. , 1999, Clinical immunology.

[42]  D. McCauley,et al.  Cystic fibrosis: scoring system with thin-section CT. , 1991, Radiology.

[43]  P. Phelan,et al.  Ventilatory mechanics in patients with bronchiectasis starting in childhood , 1974, Thorax.

[44]  E. Glauser,et al.  BRONCHIECTASIS: A REVIEW OF 187 CASES IN CHILDREN WITH FOLLOW‐UP PULMONARY FUNCTION STUDIES IN 58 , 1966, Acta paediatrica Scandinavica.

[45]  D. Hubbell,et al.  An analysis of 215 cases of bronchiectasis. , 1955, Surgery, gynecology & obstetrics.

[46]  B. Grimbacher,et al.  Activity, Severity and Impact of Respiratory Disease in Primary Antibody Deficiency Syndromes , 2013, Journal of Clinical Immunology.

[47]  G. Amsden.  Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? , 2005, The Journal of antimicrobial chemotherapy.